EAPO President Grigory Ivliev made a report at the Congress “Right to Health,” which is taking place in Moscow. The congress participants discussed intellectual property protection in the pharmaceutical industry.

Pharmaceutical inventions account for the majority of Eurasian applications filed. Therefore, the EAPO maintains the Eurasian Pharmaceutical Register to protect such patents. It includes data on patented active pharmaceutical ingredients having international nonproprietary names, and on the legal status of such patents on the territory of 8 EAPO states.

“There is a mechanism for acknowledging such information as official on the territory of the state, for example, by concluding an agreement with the EAPO. Besides, the state can independently determine the purposes and scope of information from the Pharmaceutical Register. It can also use such data when imposing restrictive measures in accordance with national legislation. Pharmaceutical companies, including Russian ones, are interested in the Pharmaceutical Register despite the common misconception that it covers only large foreign pharmaceutical sector,” Grigory Ivliev said.

The Federal Antimonopoly Service has already benefited from the Eurasian Pharmaceutical Register. It may also be useful for litigation, for efficient state procurement, and for ensuring the distributors’ activities work within the legal framework.